Resistance to Vemurafenib Can Be Reversible After Treatment Interruption: A Case Report of a Metastatic Melanoma Patient

About 40% to 60% of melanomas present BRAF mutation. Selective BRAF inhibitors such as vemurafenib and dabrafenib are currently approved for the treatment of advanced melanoma patients with BRAF mutation. The treatment-induced tumor regression occurs in the majority of patients; however, acquired re...

Descripción completa

Detalles Bibliográficos
Autores principales: Mackiewicz-Wysocka, Małgorzata, Krokowicz, Łukasz, Kocur, Jacek, Mackiewicz, Jacek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2014
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602769/
https://www.ncbi.nlm.nih.gov/pubmed/25501056
http://dx.doi.org/10.1097/MD.0000000000000157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602769/
https://www.ncbi.nlm.nih.gov/pubmed/25501056
http://dx.doi.org/10.1097/MD.0000000000000157

Ejemplares similares